Marbocare Is A New Addition To The Animalcare Livestock Range

Animalcare Ltd has extended its range of livestock products with the launch of Marbocare (marbofloxacin) 100mg/ml solution for injection. Licensed for use in cattle and pigs, Marbocare offers a unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and bovine respiratory disease (BRD) plus a single intramuscular (IM) high dose (8mg/100kg) for bovine respiratory disease. This regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle. A third-generation fluoroquinolone, developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens, proving especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis. Marbocare offers a rapid return to production with short milk withdrawal times, 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat: withdrawal is 6 days after multiple injections and 3 days after the single shot. Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits. Marbocare also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, has a 4 day meat withdrawal. “Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)”, says Tony Liepman, Product Manager from Animalcare. Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials. Animalcare advises on using the correct dose for the clinical indication and target species and encourages responsible use of fluoroquinolones on farm animals. NotesGrandemange E. et al., Field evaluation of the efficacy of marbofloxacin in the treatment of acute mastitis due to Gram-ve bacteria in the dairy cow, Cattle Practice (2002), Issue 10, Part 1, 57-62.Thomas E et al., A field comparison of the efficacy and tolerance of marbofloxacin in the treatment of BRD.JVet Pharmacol.Therapy (2001),24,353-358Eyett-Burton C., Marbofloxacin: An advanced fluoroquinolone for use in beef and dairy cattle.Cattle Practice BCVA (1997),5,4Thomas E et al Field evaluation of efficacy of a new antimicrobial, marbofloxacin in the treatment of BRD, Proceedings of the XIX World Buiatrics Congress Edinburgh (1996),54-57Marbocare®, POM-V licensed product.Endocam® , POM-V NSAID.

More from

• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
• Bake sale at Leicestershire vet practice for good cause